Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform
August 8, 2024 8:18 AM EDTEvercore ISI analyst Gavin Clark-Gartner upgraded Sarepta Therapeutics (NASDAQ: SRPT) from In Line to Outperform with a price target of $179.00 (from $185.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.
Shares of Sarepta Therapeutics closed at $140.06 yesterday.
... MoreSarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital
August 8, 2024 6:27 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $181.00 (from $182.00) while maintaining a Outperform rating.
The analyst comments "SRPT reported 2Q earnings, and we had the chance to follow up with mgmt afterwards. We came away... More
